TPST
NASD Tempest Therapeutics, Inc.$0.6350 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.6350, $0.0179 below the day’s high of $0.6529
- YTD change
- -77.87%
- vs 20-day SMA
- -22.05%
- vs 200-day SMA
- -61.31%
Price ranges
Price & Performance
-1.61 (-71.65%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.9% away from all-time highs of $533.0000
- TPST is down 78% since the beginning of the year
- TPST is down 95% over the past 12 months
- TPST is down 48% over the past 1 month
- 5% of all TPST investors are betting against TPST
TPST reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -94.3%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0155
- Last 5 days
- -19.76%
- vs 8-day SMA
- -14.78%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
